Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F23%3A00079494" target="_blank" >RIV/00159816:_____/23:00079494 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/23:00130223
Result on the web
<a href="https://www.tandfonline.com/doi/full/10.1080/1744666X.2023.2144836" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/1744666X.2023.2144836</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/1744666X.2023.2144836" target="_blank" >10.1080/1744666X.2023.2144836</a>
Alternative languages
Result language
angličtina
Original language name
Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency
Original language description
Introduction: Human immunoglobulin (IG) administered intravenously (IVIG) or subcutaneously (SCIG) is used to prevent infections in patients with primary immunodeficiency diseases (PIDDs) such as primary antibody immunodeficiencies. Areas covered: This review provides an overview of PIDD with a focus on SCIG treatment, including the properties and clinical trial results of a new SCIG 16.5% (Cutaquig, Octapharma) in pediatric patients. We also discuss the various benefits of SCIG including stable serum immunoglobulin G levels, high tolerability with fewer systemic side effects, and the flexibility of self-administration. Expert opinion: Individualized treatment for PIDD in children is necessary given the different factors that affect administration of SCIG. Variables such as the dose, dosing interval, administration sites, and ancillary equipment can be adjusted to impact the long-term satisfaction with SCIG administration in pediatric patients. The successful work that has been conducted by both professional and patient organizations to increase awareness of PIDD, especially in pediatric patients, is substantial and ongoing. The importance of early diagnosis and treatment in the pediatric patient population cannot be overstated. The safety, efficacy, and tolerability of SCIG 16.5% have been demonstrated in pediatric patients with PIDDs providing an additional therapeutic option in this vulnerable population. (C) 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Expert Review of Clinical Immunology
ISSN
1744-666X
e-ISSN
—
Volume of the periodical
19
Issue of the periodical within the volume
1
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
7-17
UT code for WoS article
000884631100001
EID of the result in the Scopus database
2-s2.0-85142213645